ABSTRACT
Purpose To establish and validate a novel fundus-controlled dark-adaptometry method.
Methods We developed a custom dark-adaptometry software for the S-MAIA device using the open perimetry interface. In the validation-substudy, participants underwent dark-adaptometry testing with a comparator device (MonCvONE, 59% rhodopsin bleach, cyan and red stimuli centered at 2°, 4°, and 6° eccentricity). Following a brief break (approx. 5 min), the participants were bleached again and underwent dark-adaptometry testing with the S-MAIA device (same loci). In the retest reliability-substudy, participants were tested twice with the S-MAIA device (same loci as above).
Nonlinear curve fitting was applied to extract dark-adaptation curve parameters. Validity and repeatability were summarized in terms of the mean bias and 95% limits of agreement (LoAs).
Results In the validation-substudy (N=20 participants, median age [IQR] 31.5 years [25.8, 62.0]), measures of rod-mediated dark-adaptation showed little to no between method differences for the cone-rod-break-time (bias [95% CI] of +0.09 min [-0.5, 0.67]), rod-intercept-time (+0.42 min [-0.51, 1.35]), and S2 slope (-0.03 LogUnits/min [-0.04, -0.02]).
In the retest reliability-substudy (N=10 participants, 32.0 years [27.0, 57.5]), the corresponding LoAs were (cone-rod-break-time) -3.01 to 2.02 min, (rod-intercept-time) -3.95 to 2.94min, and (S2 slope) -0.09 to 0.07 LogUnits/min. The LoAs for the steady-state cone and rod thresholds were -0.27 to 0.31 LogUnits and -0.32 to 0.27 LogUnits.
Conclusions The devised fundus-controlled dark-adaptometry method yields valid and reliable results. Fundus-controlled dark-adaptometry solves the critical need for localized testing of the visual cycle in eyes with unstable fixation (e.g., in the setting of subretinal gene therapy).
Competing Interest Statement
Commercial Relationships Disclosures: Jeannine Oertli:N/A Kristina Pfau: Daiichi Sankyo (C) Hendrik P.N. Scholl:Swiss National Science Foundation (#310030_201165) (F), the Wellcome Trust (PINNACLE study) (F), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study) (F), Astellas Pharma Global Development, Inc./Astellas Institute for Regenerative Medicine (S), Boehringer Ingelheim Pharma GmbH & Co (S), Gyroscope Therapeutics Ltd. (S), Janssen Research & Development, LLC (Johnson & Johnson) (S), Novartis Pharma AG (CORE) (S), Okuvision GmbH (S), and Third Rock Ventures, LLC (S), Gerson Lehrman Group (C), Guidepoint Global, LLC (C), and Tenpoint Therapeutics Limited (C), Data Monitoring and Safety Board/Committee of Belite Bio (CT2019-CTN-04690-1), ReNeuron Group Plc/Ora Inc. (NCT02464436), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561) (N) Brett G. JeffreyN/A Maximilian Pfau: Novartis (R), Janssen Pharmaceutica (C), Apellis (F,C)
Funding Statement
This research was funded by a grant of the foundation: Pro sanandis oculis, Stiftung der Basler Kantonalbank zu Gunsten des Augenspitals in Basel (awarded to M.P.), and by a Retina Suisse doctoral thesis grant (awarded to J.O.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethikkommission Nordwest-und Zentralschweiz (EKNZ) ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
